Research Analysts’ Updated EPS Estimates for February, 14th (AFX, FDC, FTV, HMY, IVTY, JACK, LXFT, NKTR, REPH, RPM)

Research Analysts’ updated eps estimates for Wednesday, February 14th:

Carl Zeiss Meditec (ETR:AFX) had its sell rating reiterated by analysts at DZ Bank AG.

First Data (NYSE:FDC) was upgraded by analysts at Robert W. Baird from a neutral rating to an outperform rating. The firm currently has $22.00 price target on the stock.

Fortive (NYSE:FTV) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $83.00 price target on the stock. According to Zacks, “Fortive’s fourth-quarter 2017 results are driven by strong revenues growth. Acquisitions contribute 5.9% to top-line growth. The company is benefiting from strength in developed markets and automation businesses in North America. Ongoing margin expansion owing to the Fortive Business System, acquisitions and strong free cash flow generation are the positives. We note that acquisitions of Industrial Scientific and Landauer is anticipated to drive recurring revenues. The company’s subscription-based radiation exposure services are focused in the medical end market. However, end market cyclicality, integration issues and uncertainties in the international markets pose concerns. In the past 12 months, the stock has underperformed the industry it belongs to.”

Harmony Gold Mining (NYSE:HMY) was upgraded by analysts at HSBC Holdings plc from a hold rating to a buy rating.

Invuity (NASDAQ:IVTY) had its buy rating reiterated by analysts at Northland Securities. The firm currently has a $6.00 price target on the stock. The analysts wrote, “We would be remiss in not expressing our disappointment, and are lowering our PT to $6.””

Jack in the Box (NASDAQ:JACK) was upgraded by analysts at OTR Global to a positive rating.

Luxoft (NYSE:LXFT) was downgraded by analysts at Cowen Inc from an outperform rating to a hold rating. The firm currently has $50.00 price target on the stock.

Nektar Therapeutics (NASDAQ:NKTR) had its buy rating reiterated by analysts at Mizuho. Mizuho currently has a $89.00 target price on the stock. The analysts wrote, “We expect both Nektar and BMY to jointly report clinical data going forward.””

CIBC initiated coverage on shares of Recro Pharma (NASDAQ:REPH). The firm issued an outperform rating and a $19.00 price target on the stock.

RPM International (NYSE:RPM) was upgraded by analysts at Vertical Research from a hold rating to a buy rating.

Stora Enso OYJ (OTCMKTS:SEOAY) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $19.00 target price on the stock. According to Zacks, “Stora Enso is an integrated forest products company producing magazine papers, newsprint, fine papers and packaging boards, areas in which the Group is a global market leader. Stora Enso also conducts extensive sawmilling operations. To strengthen its market position and better serve customers in the United States, the company acquired the U.S.-based, Consolidated Papers, Inc. in 2000. “

Simmons First National (NASDAQ:SFNC) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “SIMMONS FIRST NATIONAL CORP bank holding company registered under the Bank Holding Act of 1956. Through its subsidiaries, Co. provides a full range of banking and mortgage services to individual and corporate customers. “

Select Income REIT (NASDAQ:SIR) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Select Income REIT is a real estate company formed to primarily own and invest in net leased, single tenant properties. It has properties in Oahu, Hawaii and the mainland United States. Select Income REIT is headquartered in Newton, MA. “

Semiconductor Manufacturing Int'l (NYSE:SMI) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “SEMICONDUCTOR MANUFACTURING INTERNATIONAL CORPORATION is one of the leading semiconductor foundries in the world and the largest and most advanced foundry in Mainland China, providing integrated circuit manufacturing service at 0.35 micron to 65 nanometer and finer line technologies. Headquartered in Shanghai, China, SMIC has a 300-millimeter wafer fabrication facility (fab) and three 200 mm wafer fabs in its Shanghai mega-fab, two 300 mm wafer fabs in its Beijing mega-fab, a 200 mm wafer fab in Tianjin, and an in-house assembly and testing facility in Chengdu. SMIC also has customer service and marketing offices in the U.S., Europe, and Japan, and a representative office in Hong Kong. In addition, SMIC manages and operates a 200 mm wafer fab in Chengdu owned by Cension Semiconductor Manufacturing Corporation and a 300 mm wafer fab under construction in Wuhan owned by Wuhan Xinxin Semiconductor Manufacturing Corporation. “

Snap-on (NYSE:SNA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $178.00 target price on the stock. According to Zacks, “Snap-On’s fourth-quarter 2017 earnings trumped the Zacks Consensus Estimate and rose 8.9% from the year-ago figure. The company is committed to its RCI program, which has been instrumental in fuelling sales, margins and savings in the recent quarters. Going forward, the company plans to boost growth by focusing on franchise network, expanding footprint in vehicle repair garage & vital industries, and penetrating emerging markets. Diversified portfolio and impressive traction of new products add to its strength. Also, the company has been witnessing encouraging prospects in most of its business lines that will likely unlock new growth avenues going forward. Despite these positives, year to date, Snap-on’s shares have underperformed the industry average. Sluggish oil market activities, volatility in the prices and high currency fluctuation risks pose as major concerns.”

Sanofi (NYSE:SNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Sanofi’s fourth-quarter 2017 results were below expectations as it missed estimates for both earnings and sales. Sanofi’s Diabetes franchise is under significant pressure with key product, Lantus facing increasing competitive pressure at the payor level and the presence of biosimilar competition in several European markets and Japan. The declining trends in the diabetes franchise are expected to continue in 2018. Meanwhile, the performance of the Consumer Healthcare franchise was soft n 2017. Moreover, Sanofi’s shares have underperformed the industry in 2017. Other headwinds include generic competition and slower-than-expected uptake of new products like Praluent. However, Sanofi's focus on streamlining its business and pursuing business development deals is encouraging. Further, the recently announced acquisitions of Ablynx and Bioverativ are expected to strengthen Sanofi’s position in the rare blood disorders market.”

Sumitomo Heavy Industries (OTCMKTS:SOHVY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Sumitomo Heavy Industries, Ltd. manufactures and markets heavy machinery. The Company’s operations include heavy machinery, shipbuilding, mass-production machinery, environmental equipment, and construction machinery divisions. Sumitomo Heavy Industries, Ltd. is headquartered in Tokyo, Japan. “

Spero Therapeutics (NASDAQ:SPRO) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. “

S & T Bancorp (NASDAQ:STBA) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “S & T BANCORP, INC. is a bank holding company which is engaged in general banking business. The Bank is a full service bank with its main office in Indiana, Pennsylvania, providing service to its customers through a branch of 34 offices located in Armstrong, Allegheny, Indiana, Jefferson, Clearfield and Westmoreland counties. The Bank’s services include accepting time and demand deposit accounts, making secured and unsecured commercial and consumer loans, providing letters of credit, and offering discount brokerage services, personal financial planning and credit card services. “

Receive News & Ratings for Carl Zeiss Meditec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply